Key Points
- Director Bonnie Bassler sold 1,500 Regeneron shares on Jan. 7 at an average price of $800 for a total of $1.2 million, reducing her holdings by 46.83% to 1,703 shares, according to an SEC filing.
- Regeneron has seen broad analyst upgrades and price-target increases (Bank of America upgraded to Buy with a $860 target), shares recently hit a 52-week high, and the consensus target is about $791.05.
- The company beat recent quarter expectations with EPS of $11.83 vs. $9.73 est. and revenue of $3.75 billion vs. $3.57 billion est.; Regeneron has a market cap of ~$84.2 billion and a P/E of ~19.2.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) Director Bonnie Bassler sold 1,500 shares of the company's stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Regeneron Pharmaceuticals Stock Down 1.4%
Shares of REGN opened at $801.01 on Friday. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The firm has a fifty day moving average price of $735.23 and a 200-day moving average price of $626.08. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $816.99. The firm has a market capitalization of $84.19 billion, a P/E ratio of 19.18, a P/E/G ratio of 2.42 and a beta of 0.39.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm's revenue was up .9% on a year-over-year basis. During the same period in the prior year, the company earned $12.46 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.43%.
Analyst Ratings Changes
A number of analysts recently commented on the company. UBS Group increased their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a "neutral" rating in a research note on Friday, November 7th. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 29th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a "buy" rating in a research note on Wednesday, October 29th. Canaccord Genuity Group upped their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a "buy" rating in a report on Thursday, December 4th. Finally, Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Monday, November 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $791.05.
Check Out Our Latest Research Report on REGN
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Bank of America upgraded REGN from "Underperform" to "Buy" and raised its price target to $860, citing improving fundamentals and multiple 2026 catalysts — a major analyst reversal that boosts buy-side confidence. Regeneron upgraded by Bank of America
- Positive Sentiment: Shares hit a new 52-week high following recent analyst upgrades, signaling momentum and renewed institutional interest. Regeneron Hits New 52-Week High
- Positive Sentiment: Truist raised its price target to $820 and keeps a "Buy" rating, adding incremental upward pressure to consensus valuation. Truist raises price target
- Positive Sentiment: Broader analyst coverage has tilted more favorable (multiple firms raising ratings/targets and 21-analyst summaries highlighting improving outlook), supporting demand from momentum and fundamental buyers. 21 analysts assess REGN
- Positive Sentiment: Zacks highlights Regeneron's history of beating estimates and argues the firm has the setup to beat again, which can lift expectations heading into future earnings. Zacks on earnings
- Neutral Sentiment: Unusual options activity was observed, indicating elevated trader interest/hedging around recent news — can amplify short-term volatility but is ambiguous on direction. Unusual options activity
- Neutral Sentiment: Comparative coverage (e.g., REGN vs ILMN) offers valuation context for investors but is not an immediate catalyst. REGN vs ILMN analysis
- Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at ~$800 (filed with the SEC), which can be viewed negatively by some investors even though the dollar amount is modest relative to market cap. Insider sale SEC filing
Institutional Investors Weigh In On Regeneron Pharmaceuticals
A number of hedge funds have recently made changes to their positions in REGN. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $31,000. Salomon & Ludwin LLC acquired a new position in Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Caitlin John LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Finally, Traub Capital Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $38,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Regeneron Pharmaceuticals Company Profile
(
Get Free Report)
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
